Denali Therapeutics
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 445
- Market Cap
- -
- Introduction
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)
- Conditions
- Parkinson Disease
- Interventions
- Drug: BIIB122 225 mgOther: BIIB122-Matching Placebo
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Denali Therapeutics Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT06602193
- Locations
- 🇺🇸
Evergreen Health Laboratory, Kirkland, Washington, United States
🇺🇸Parkinson's Disease and Movement Disorders Center, Boca Raton, Florida, United States
🇺🇸Inland Northwest Research, Spokane, Washington, United States
A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-DNL343 Following a Single Oral Dose in Healthy Male Participants
- Conditions
- Healthy Volunteers
- Interventions
- Drug: [14C]-DNL343
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Denali Therapeutics Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT06281158
- Locations
- 🇺🇸
Clinical Site, Madison, Wisconsin, United States
Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)
- Conditions
- Mucopolysaccharidosis Type IIIA
- Interventions
- Drug: DNL126
- First Posted Date
- 2023-12-26
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Denali Therapeutics Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT06181136
- Locations
- 🇺🇸
University of Iowa Stead Family Children's Hospital, Iowa City, Iowa, United States
🇺🇸UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
🇺🇸University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Denali Therapeutics Inc.
- Target Recruit Count
- 99
- Registration Number
- NCT06075537
- Locations
- 🇫🇷
Hopital Jeanne De Flandre - Metabolic Diseases Unit, Lille, France
🇪🇸Hospit U. Vall d'Hebron - PPDS, Barcelona, Spain
🇧🇪UZ Brussel, Jette, Belgium
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL919 in Healthy Participants
- Conditions
- Healthy Participant
- Interventions
- Drug: DNL919Drug: Placebo
- First Posted Date
- 2022-07-08
- Last Posted Date
- 2023-08-16
- Lead Sponsor
- Denali Therapeutics Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT05450549
- Locations
- 🇳🇱
Centre for Human Drug Research (CHDR), Leiden, South Holland, Netherlands
A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) Vs Idursulfase in Pediatric and Young Adult Participants with Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)
- Conditions
- Mucopolysaccharidosis II
- Interventions
- First Posted Date
- 2022-05-12
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Denali Therapeutics Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT05371613
- Locations
- 🇸🇪
Drottning Silvias Barn Och Ungdomssjukhus, Göteborg, Sweden
🇹🇷Cukurova University Medical Faculty Balcali Hospital, Adana, Turkey
🇹🇷Gazi Universitesi Tip Fakultesi, Çankaya, Turkey
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants with Frontotemporal Dementia (FTD-GRN)
- Conditions
- Frontotemporal Dementia
- Interventions
- Drug: PlaceboDrug: DNL593
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Denali Therapeutics Inc.
- Target Recruit Count
- 106
- Registration Number
- NCT05262023
- Locations
- 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇧🇪University of Antwerp, Antwerp, Belgium
🇧🇪UZ Leuven, Leuven, Belgium
A Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral Sclerosis
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Drug: PlaceboDrug: DNL343
- First Posted Date
- 2021-08-16
- Last Posted Date
- 2023-01-17
- Lead Sponsor
- Denali Therapeutics Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05006352
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Atrium Health Neurosciences Institute, Charlotte, North Carolina, United States
🇺🇸PPD Orlando, Orlando, Florida, United States
A Study to Evaluate the Bioavailability and Safety of DNL343 in Healthy Volunteers
- First Posted Date
- 2020-10-09
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- Denali Therapeutics Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT04581772
- Locations
- 🇳🇿
Auckland Clinical Studies Ltd., Grafton, Auckland, New Zealand
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL151 in Healthy Volunteers
- Conditions
- Healthy Volunteers
- Interventions
- Drug: DNL151Drug: Placebo
- First Posted Date
- 2020-09-22
- Last Posted Date
- 2022-03-07
- Lead Sponsor
- Denali Therapeutics Inc.
- Target Recruit Count
- 186
- Registration Number
- NCT04557800
- Locations
- 🇳🇱
PRA Health Sciences, Van Swietenlaan, Groningen, Netherlands
🇳🇱Centre for Human Drug Research, Leiden, South Holland, Netherlands